Interventions
DIE, abnormal endometrial thickness
STERILE, PROLIFERATIVE, REGRESSION, PATHOLOGY, ATROPHIC
Enrolled patients were randomly allocated into two groups; group I got DIE 2 mg/day (orally Visanne; bayer pharma, Cairo, Egypt) for 14 days (10th to the 25th day of cycle) while Between the 16th and 25th day of the cycle, group II got norethisterone acetate (NETA) 15 mg/d (orally Primolut Nor; Hi Pharma, Cairo, Egypt) for 10 days. Both groups continued the therapy for six months.A list of random numbers created by a computer was used for randomization. The QuickCalcs program was used to create the random number list (GraphPad Software Inc, La Jolla, California). The research supervisor stored the group assigning numbers in an envelope that was sealed.Clinical evaluation and history-taking are performed on all women. In addition, a transvaginal ultrasound was used, and women with abnormal endometrial thickness underwent biopsy using the Pipelle Endometrial Suction Curette (Cooper Surgical Inc., Trumbull, CT 06,611 USA). The Pipelle is a single-use, sterile, plastic, disposable, suction curette consisting of an outer graded sheath and an inner piston for obtaining a histologic biopsy of the uterine mucosa lining or sample extraction of uterine menstrual content for microscopic examination or culturing. The Pipelle had outer diameter (OD) of 3.1 mm and no cervical dilatation needed. The biopsy sample was then examined by the unit of pathology. All women followed-up for six months then the second biopsy and histopathology were done.The pathologic outcomes of endometrial curettages were compared (both during and after therapy, respectively). The outcomes were divided into four groups: advancement (simple EH without atypia), persistence (atrophic, inactive, secretory endometrium), regression (proliferative endometrial) (simple EH atypia, complicated EH atypia, or neither).